RAP-219
- Focal Onset Seizures
- Bipolar Mania
- Undisclosed indication
- Primary Generalized Tonic-Clonic Seizures
Market cap $1.41B 59.3M shares (10-Q, Nov 2, 2026) × $23.76 close Nov 17, 2026
Most recent annual filing: 2026-03-10
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Precision small molecule drug discovery platform based on receptor associated proteins (RAPs) in the brain, enabling neuroanatomical specificity through selective targeting of RAPs expressed in discrete brain regions; focus on neurological and psychiatric disorders including epilepsy, bipolar mania, chronic pain, migraine, and hearing/vestibular disorders.
Targets: TARPγ8, AMPAR, α6β4 nAChR, α6β4 nicotinic acetylcholine receptor
Receptor Associated Protein (RAP) technology platform enabling discovery of small molecule precision medicines targeting neuronal receptor complex components for increased selectivity and neuroanatomical specificity; focus areas include epilepsy, psychiatric disorders, chronic pain, migraine, and hearing/vestibular disorders
Targets: TARPγ8, nAChR α6β4, α9α10, AMPAR, nAChR α9α10
Receptor Associated Protein (RAP) biology platform enabling discovery of precision small molecule neuromedicines. Uses RAPs to unlock previously inaccessible neuronal receptor targets with neuroanatomical specificity. Focus areas: epilepsy, bipolar disorder, chronic pain, migraine, hearing and vestibular disorders, and broader neurological/psychiatric diseases.
Targets: TARP γ8, α6β4 nAChR, α9α10 nAChR
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Every verdict Biotech Distilled has published on Rapport Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
“We plan to have a meeting with the FDA in the first quarter of 2027 to discuss the Phase 2 data and registrational trial design for RAP-219 in adults experiencing acute mania associated with BD.”matched to RAP-219 (bipolar mania) · regulatory submission
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. No press release captured yet; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →